New Drug Information Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

BETHESDA, Md-Patients have a new, reliable source for information about drugs. The National Library of Medicine has added the US Pharmacopeia’s Drug Information, Vol. II, “Advice for the Patient,” to its MEDLINEplus website. The publication provides extensive information about more than 9,000 brand name, generic prescription, and over-the-counter medications, written in nontechnical language. The information is available at http://medlineplus.gov.

BETHESDA, Md—Patients have a new, reliable source for information about drugs. The National Library of Medicine has added the US Pharmacopeia’s Drug Information, Vol. II, “Advice for the Patient,” to its MEDLINEplus website. The publication provides extensive information about more than 9,000 brand name, generic prescription, and over-the-counter medications, written in nontechnical language. The information is available at http://medlineplus.gov.

Articles in this issue
Couric Urges Doctors to Talk to Patients About Colon Cancer
Automated Imaging Notification System Close to Fail-Safe
Higher Dairy Consumption Linked to Prostate Cancer Risk
First-Year Funding of Early Detection Research Network Complete
Gritty Antitobacco Ads and More From Legacy Foundation
Tositumomab Effective for Low-Grade Follicular Lymphoma
New Awards Spotlight Courage of Cancer Survivors
Hospital Volume Shown to Predict Breast Cancer Outcome
New Drug Information Website
NCCN Presents Updated Colorectal Cancer Guidelines
Taxol Teamed With Herceptin Tested Against Prostate Cancer
Adding Paclitaxel to Adjuvant FAC in Operable Breast Cancer May Lower Risk of Recurrence
Trend Toward Improved Outcomes With 5-FU/LV Plus RhuMabVEGF in Colorectal Cancer
Weekly Taxol/Herceptin: 60% RR in Metastatic Breast Cancer
Colonoscopy vs Sigmoidoscopy in Asymptomatic Women
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Tim Cortese
August 7th 2025
Article

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 7th 2025
Article

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.